Phaseline

Companies › Tonghua Dongbao Pharmaceutical

Tonghua Dongbao Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
THDBH120 injection–Phase 2Overweight or Obese–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07036601THDBH120 injectionPhase 2Overweight or ObeseMetabolic and endocrineFeb 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zhuhai Rui-Inno Pharmaceutical Technology Portal Therapeutics Op-T Housey Healthcare ULC Mankind Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.